-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Pyxis Oncology, Lowers Price Target to $5

Benzinga·12/19/2025 15:17:53
Listen to the news
RBC Capital analyst Leonid Timashev maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $8 to $5.